News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

Neoadjuvant T-DXd achieves modest pCR in HER2-low, HR-positive early-stage breast cancer
11 Nov 2026
byStephen Padilla
Neoadjuvant treatment with the HER2-directed antibody drug conjugate trastuzumab deruxtecan-nxki (T-DXd), whether alone or with endocrine therapy or chemotherapy, results in low pathologic complete response (pCR) rates in patients with HER2-low, hormone receptor (HR)-positive early-stage breast cancer, as shown in the TALENT trial.
11 Nov 2026

Personalized mRNA cancer vaccine + pembrolizumab hits targets in phase III melanoma trial
10 Nov 2026
byAudrey Abella
In the large phase III INTerpath-001 study evaluating individuals with resected stage IIB–IV melanoma, recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) improved when the mRNA-based individualized neoantigen therapy intismeran autogene was added to pembrolizumab compared with pembrolizumab alone.
10 Nov 2026






